Published by

British Journal of Contemporary Research

BEXFORD PUBLISHING

Tuberculosis in the Diabetic Patient: A Diagnostic Dilemma

Review Article | Volume 1 | Issue 2 | 2026 | Article Number: 044

Accepted: 03 July 2026 | Published: 10 July 2026 | ISSN: 2979-8582 (Online)

Crossref doi : **https://doi.org/10.67693/BJCR-ZKYFCR7V**

Dr. Onuoha-Ojeamiren Gloria Olomiekido[1], Dr. Onuoha Augunus Chidubem[2], Iduda Ojeamiren[3], Ajay kumar P[4], Samuel Olowo Sunday[1]

[1]Department of Medical Microbiology, Faculty of Basic Clinical Science, Ambrose Alli University, Ekpoma , Nigeria,
[2]Department of Chemical Pathology, Faculty of Basic clinical Sciences, Ambrose Alli University Ekpoma, Nigeria,
[3]Department of Laboratory Sciences, Dartford and Gravesham NHS Trust, Kent,
[4]Department of Laboratory Medicine, Central Hospital, South Western Railway, Hubli, Karnataka, India,

DOGO 0000-0003-2236-6014, DOAC 0009-0005-6632-3149

Correspondence: Dr. Onuoha-Ojeamiren Gloria Olomiekido, gloriaonoha2@gmail.com

Abstract

Tuberculosis (TB) and diabetes mellitus (DM) overlapping burden is now a growing clinical problem , complicating both early diagnosis and effective treatment. Diabetes increases the risk of TB disease and may worsen clinical outcomes, making early recognition essential. [1],[2],[3] Because symptoms may be atypical and standard tests may be less straightforward in some patients; a high index of suspicion and integrated screening are important. [4],[5]

Keywords: Tuberculosis, Diabetes Mellitus, Diagnostic Dilemma, Screening, Glycemic Control, Comorbidity

Introduction

Tuberculosis continues to account for significant illness and death globally, while the prevalence of diabetes is rising rapidly, especially in low- and middle-income countries where the TB burden is also high. [3], [5] The coexistence of both diseases is clinically important because diabetes is a recognized risk factor for TB and can complicate presentation, diagnosis, and recovery.[2],[6]

WHO developed a collaborative framework for TB and diabetes because management requires coordinated action at both the clinical and programmatic levels.[3],[4] This framework emphasizes collaboration, detection and management of TB in people with diabetes, and detection and management of diabetes in people with TB.[3],[4]

© 2026 The Authors. Published by Bexford Publishing Ltd

Epidemiology

The burden of TB-diabetes comorbidity is rising because both conditions are increasingly prevalent in the same populations.[2,5] Recent evidence shows that diabetes is associated with a higher risk of active TB disease.[2,6,7] A 2021 systematic review and meta-analysis found a substantial burden of diabetes among TB patients and showed worse outcomes in the TB-diabetes group.[1,2,5]

This overlap is especially concerning in settings with limited diagnostic capacity and high TB transmission, because missed TB in diabetic patients may allow ongoing spread.[3,5] The growing diabetes burden may therefore threaten TB control gains if integrated screening is not consistently implemented.[0,1,3,5]

Pathophysiology

Diabetes impairs host immunity by affecting macrophage function, cytokine signaling, and cellular immune responses needed to contain *Mycobacterium tuberculosis*.[5,6] Hyperglycemia and insulin resistance can further weaken the immune response and may contribute to more severe disease.[6, 7]

The relationship is reciprocal. Active TB can worsen glucose control through inflammation, stress responses, nutritional compromise, and treatment-related effects.[6, 8] Therefore, the clinician must manage TB and diabetes as interdependent conditions rather than separate problems.[3, 4]

Diagnostic dilemma

The central diagnostic problem is that TB in diabetic patients may present in an atypical or attenuated manner.[6,8] Common symptoms associated with TB such as cough, fever, night sweats, fatigue, and cachexia are non-specific and may be attributed to diabetes or another chronic condition.[5,6] Radiographic findings may also be less classic, and bacteriologic confirmation may be delayed or initially negative.[6,8]

Diabetes-related immune dysfunction may also reduce the performance of some TB diagnostic tests, contributing to underdiagnosis and delayed treatment.[4,5] This is especially relevant for TB infection testing, early disease, and extrapulmonary forms where clinical suspicion is critical.[4,9] The key practical point is that TB should remain on the differential diagnosis in any diabetic patient with persistent respiratory or constitutional symptoms.[5,6]

Clinical presentation

Diabetic patients with TB may present with prolonged cough, unexplained weight loss, low-grade fever, reduced appetite, hemoptysis, or constitutional symptoms that do not resolve with routine care. [5,8] in some cases, chest imaging may show cavitary disease or infiltrates, but in others the pattern may not be obvious. [7,8] suboptimal glycaemic control is often associated with severe illness and slower recovery.[1,7]

Latent TB infection should also be considered in selected high-risk diabetic patients, especially in settings with high TB prevalence.[4,9] This does not mean every patient with diabetes needs the same workup, but the threshold for considering TB infection should be lower when epidemiologic risk is high.[3,4]

Diagnostic approach

A structured diagnostic approach is essential. In a diabetic patient with chronic cough, fever, night sweats, weight loss, hemoptysis, or unexplained radiographic findings, TB testing should be initiated promptly. [5, 6] Diagnostic workup should include sputum microscopy, culture, and molecular testing when available.[5,6]

If initial evaluation is negative but suspicion remains high, repeat testing or additional investigations should be pursued rather than stopping the workup.[5,6] In high-risk diabetic patients, clinicians may also consider testing for TB with tuberculin skin test or interferon-gamma release assays when appropriate.[4,9]

© 2026 The Authors. Published by Bexford Publishing Ltd

The diagnostic strategy should be adapted to local resources, but it should never be passive or delayed.[3,4]

Screening and integration

Bidirectional screening is one of the most important strategies for improving case detection.[3,4] Patients with TB should be screened for diabetes, while patients with diabetes who have TB symptoms or epidemiological risk factors should be screened for TB.[3,5] WHO guidance emphasizes that coordinated detection and management of both conditions should occur at the organizational and clinical levels.[3,4]

Integrated care is especially important because isolated TB treatment without glucose optimization may lead to poorer outcomes.[2,7,10] Similarly, diagnosing diabetes without considering TB can miss a serious underlying infection.[5,6] A combined approach reduces delay, improves communication between services, and supports earlier intervention.[3,4]

Diabetes management during TB treatment

Diabetes management during TB treatment should focus on achieving stable glycemic control while minimizing drug interactions and treatment toxicity.[1,5,7] Metformin is commonly preferred in many patients because it has no major interaction with rifampicin and may have additional beneficial effects, although renal and hepatic function should be monitored.[1,2,7] Insulin is often needed for severe hyperglycemia, especially when oral therapy is insufficient or when rapid control is required.[1,2,7]

Cardiovascular risk assessment is also important in TB-DM patients because diabetes adds long-term vascular risk even during acute infection.[1,7] Effective diabetes management should therefore include glucose monitoring, medication adjustment, nutrition counseling, and follow-up after TB treatment completion.[1,2,7]

Preventing diabetes in the TB patient

Prevention of diabetes in TB patients is best approached through lifestyle modification, nutritional support, and reduction of modifiable metabolic risk factors.[2,5] TB illness may worsen nutrition and physical inactivity, which can increase the risk of poor glucose control and future diabetes in vulnerable patients.[5,6]

Health services should use TB care as an opportunity for metabolic risk screening, education on diet and exercise, and referral for long-term prevention when needed.[1,2,8] Patients with TB, especially those with risk factors such as overweight, family history, or prior hyperglycemia, may benefit from follow-up glucose testing after completion of TB therapy.[1,2,8] This helps detect new-onset diabetes early and reduces the likelihood of missed chronic disease.[1,2,8]

Public health implications and strategies

TB-diabetes comorbidity is not only a clinical problem but also a public health issue.[3,5] The combined burden can increase transmission, worsen outcomes, and stretch already limited health system resources.[2,3,5,7] Public health strategies should therefore prioritize bidirectional screening, integrated care pathways, and surveillance systems that capture both diseases together.[2,3,7]

WHO guidance supports people-centred services that mainstream collaborative TB/DM activities within national guidelines and standard operating procedures.[5,7] Health systems should also strengthen referral networks so that patients diagnosed with one condition are promptly assessed for the other.[3,5] These strategies are especially important in high-burden settings where delayed diagnosis has a larger community impact.[3,5]

Policy and funding

Policy support is essential because sustainable TB-DM control requires coordinated financing, guideline

© 2026 The Authors. Published by Bexford Publishing Ltd

development, and program integration.[3,5] WHO and related policy brief materials emphasize that primary health care platforms should integrate community-based diabetes screening alongside TB symptom screening.[3,5] Without policy backing, TB and diabetes programs tend to operate separately, which reduces efficiency and increases missed cases.[3,5,7]

Funding priorities should include staff training, screening tools, integrated data systems, and referral infrastructure.[5] Historically, estimates have shown that adding diabetes care to TB programs requires additional resources, but these investments may prevent worse downstream costs from treatment failure, relapse, and prolonged illness.[5] Countries should therefore treat TB-DM integration as a cost-effective public health investment rather than an optional add-on.[5,7]

Public awareness and education

Public awareness is crucial because both TB and diabetes can be under-recognized until disease is advanced.[2,5,6] Community education should explain that persistent cough, weight loss, and fever need prompt assessment, especially in people with diabetes or other risk factors.[5,2] Health messaging should also reinforce that good glucose control supports better TB outcomes and that TB can affect overall metabolic health.[1,2,7]

Education should target patients, families, community health workers, and front-line clinicians.[5,6] When people understand that TB and diabetes interact, they are more likely to seek care early, adhere to treatment, and return for screening after recovery.[2,5,6] This helps reduce stigma, delay, and preventable complications.[5,6]

Conclusion

Tuberculosis in the diabetic patient remains a true diagnostic dilemma because diabetes increases susceptibility, changes presentation, and may reduce diagnostic performance.[5,6] Early suspicion, appropriate microbiologic testing, bidirectional screening, and coordinated management of glycemia and TB are essential to improve outcomes.[3,4,7] In high-burden settings, integrated TB-diabetes care should be treated as a priority, not an optional addition.[3,5]

References

Alisjahbana, B., Sahiratmadja, E., Nelwan, E. J., et al. (2007). The effect of type 2 diabetes mellitus on the presentation and treatment response of pulmonary tuberculosis. *Clinical Infectious Diseases, 45*(4), 428–435.

Baker, M. A., Harries, A. D., Jeon, C. Y., et al. (2011). The impact of diabetes on tuberculosis treatment outcomes: A systematic review. *BMC Medicine, 9*, 81.

Centers for Disease Control and Prevention. (2024). *Tuberculosis and diabetes.*

Diabetes among tuberculosis patients and its impact on tuberculosis treatment in South Asia: A systematic review and meta-analysis. (2021). *PubMed.*

Diabetes screening among people with tuberculosis. (2026). *PubMed Central (PMC).*

Dooley, K. E., & Chaisson, R. E. (2009). Tuberculosis and diabetes mellitus: Convergence of two epidemics. *The Lancet Infectious Diseases, 9*(12), 737–746.

European Centre for Disease Prevention and Control. (2011). *Use of interferon-gamma release assays in support of TB diagnosis.*

© 2026 The Authors. Published by Bexford Publishing Ltd

Foe-Essomba, J. R., Kenmoe, S., et al. (2021). Diabetes mellitus and tuberculosis: A systematic review and meta-analysis with sensitivity analysis for studies comparable for confounders. *PLoS ONE, 16*(12), e0261246.

Jeon, C. Y., & Murray, M. B. (2008). Diabetes mellitus increases the risk of active tuberculosis: A systematic review of 13 observational studies. *PLoS Medicine, 5*(7), e152.

Kumar, A., et al. (2022). Screening for diabetes mellitus in tuberculosis patients: An evidence-based update. *Indian Journal of Medical Research, 156*(1–2), 17–25.

Lin, Y., Harries, A. D., Kumar, A. M. V., et al. (2017). Management of diabetes mellitus-tuberculosis. *The International Journal of Tuberculosis and Lung Disease, 21*(4), 479–487.

Magee, M. J., Salindri, A. D., Rustad, S. D., et al. (2019). Diabetes mellitus and tuberculosis. *Clinics in Chest Medicine, 40*(4), 887–901.

Navigating the dual burden of diabetes mellitus and tuberculosis: A comprehensive review of clinical and public health strategies. (2025). *PubMed.*

Niazi, A. K., & Kalra, S. (2012). Diabetes and tuberculosis: A review of the role of optimal glycemic control. *Journal of Diabetes & Metabolic Disorders, 11*, 28.

Prevalence of diabetes among patients with tuberculosis in China. (2021). *PubMed.*

Ruslami, R., Andriani, A., Adi, L., et al. (2018). Clinical management of combined tuberculosis and diabetes. *PubMed.*

The Impact of optimal glycemic control on tuberculosis treatment outcomes. (2024). *JMIR Public Health and Surveillance.*

The Union. (2011). *The WHO/Union collaborative framework for TB and diabetes.*

Tuberculosis and diabetes: Current state and future perspectives. (n.d.). *Wiley.*

Tuberculosis and diabetes mellitus: The complexity of a syndemic. (2024). *PubMed.*

Tuberculosis risk among people with diabetes mellitus in Sub-Saharan Africa: A systematic review. (2022). *PubMed.*

Tuberculosis treatment challenges in TB-diabetes comorbidities. (2024). *PubMed.*

University of Queensland Library. (n.d.). *In-text citations: Vancouver (AMA) referencing.*

Wang, C., Yu, C., Shen, H., et al. (2020). Tuberculosis and diabetes mellitus: Evidence from the past decade and future perspectives. *Journal of Diabetes Research, 2020*, 5137981.

World Health Organization. (2011). *Collaborative framework for care and control of tuberculosis and diabetes.*

World Health Organization. (2022). *WHO policy brief on integrating diabetes screening with TB symptom screening.*

World Health Organization. (2023). *WHO TB-DM people-centred services guidance.*

©2026 by the authors. Submitted for possible open access publication under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by-nc-sa/4.0/).\